Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
Lee IH, Lee SJ, Kang B, Lee J, Jung JH, Park HY, Park JY, Park NJ, Kim EA, Kang J, et al. Breast Cancer Res Treat. 2024 May; 205(1):181-191. Epub 2024 Jan 27.